Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Roivant Sciences (ROIV) Operating Leases (2021 - 2025)

Roivant Sciences' Operating Leases history spans 5 years, with the latest figure at $98.5 million for Q4 2025.

  • For Q4 2025, Operating Leases rose 8.87% year-over-year to $98.5 million; the TTM value through Dec 2025 reached $98.5 million, up 8.87%, while the annual FY2025 figure was $90.3 million, 100.64% up from the prior year.
  • Operating Leases reached $98.5 million in Q4 2025 per ROIV's latest filing, up from $89.8 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $98.5 million in Q4 2025 to a low of $43.2 million in Q3 2024.
  • Average Operating Leases over 5 years is $64.1 million, with a median of $61.2 million recorded in 2021.
  • Peak YoY movement for Operating Leases: decreased 17.06% in 2022, then surged 108.02% in 2025.
  • A 5-year view of Operating Leases shows it stood at $62.1 million in 2021, then decreased by 11.54% to $54.9 million in 2022, then dropped by 14.32% to $47.1 million in 2023, then skyrocketed by 92.27% to $90.5 million in 2024, then rose by 8.87% to $98.5 million in 2025.
  • Per Business Quant, the three most recent readings for ROIV's Operating Leases are $98.5 million (Q4 2025), $89.8 million (Q3 2025), and $90.3 million (Q2 2025).